Cargando…
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
This retrospective study, utilizing U.S. electronic health record (EHR) data from January 2013 to December 2020, sought to assess whether rivaroxaban and apixaban had similar effectiveness and safety in the treatment of cancer-associated venous thromboembolism (VTE) in patients with a cancer type no...
Autores principales: | Caroti, Kimberly Snow, Becattini, Cecilia, Carrier, Marc, Cohen, Alexander T., Ekbom, Anders, Khorana, Alok A., Lee, Agnes Y.Y., Brescia, Christopher, Abdelgawwad, Khaled, Psaroudakis, George, Rivera, Marcela, Schaefer, Bernhard, Brobert, Gunnar, Coleman, Craig I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332896/ https://www.ncbi.nlm.nih.gov/pubmed/37435565 http://dx.doi.org/10.1055/s-0043-1770783 |
Ejemplares similares
-
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023) -
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program
por: Caroti, Kimberly Snow, et al.
Publicado: (2023) -
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
por: Coleman, Craig I., et al.
Publicado: (2021) -
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
por: Bauersachs, Rupert, et al.
Publicado: (2020) -
Bleeding and Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation Treated with Apixaban or Rivaroxaban
por: ABDULLAH, Ahmad Salihin, et al.
Publicado: (2022)